Showing results (1831-1840 of 1,894) with videos related to
Sort By:
Pageof 190
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC|September 19, 2009
Initial evaluation and referral guidelines for management of pelvic/ovarian massesTien Le, Christopher Giede, Shia Salem, et al.Drug and Alcohol Dependence|November 10, 2018
Approaches for creating comparable measures of alcohol use symptoms: Harmonization with eight studies of criminal justice populationsAndrea M Hussong, Nisha C Gottfredson, Dan J Bauer, et al.Journal of the National Cancer Institute|March 5, 2020
Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN)Tamara Jamaspishvili, Palak G Patel, Yi Niu, et al.Psychiatry Research|June 1, 2025
A pilot randomized controlled trial of a digital cannabis harm reduction intervention for young adults with first-episode psychosis who use cannabisStephanie Coronado-Montoya, Amal Abdel-Baki, Paule Bodson-Clermont, et al.European Urology Oncology|September 25, 2025
Prognostic Significance of the Cytoplasmic Expression of UDP-glucuronosyltransferase 2B17 in Localized Prostate Cancer: Insights from the Canadian Prostate Cancer Biomarker Network and PROCURE Multi-institutional CohortsAshwini Uchil, Louis Lacombe, Hélène Hovington, et al.The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.The New England Journal of Medicine|October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsKeith T Flaherty, Jeffery R Infante, Adil Daud, et al.Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.British Journal of Pharmacology|May 1, 1997
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitorD Riendeau, M D Percival, S Boyce, et al.Pageof 190